ArticleFrontiers in oncology2020

Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay.

Timothy W Farren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.